{"filings":[{"id":1177516,"accession_number":"0001493152-26-029504","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-06-22T12:30:19+00:00","items":["5.07"],"status":"ready","headline":"Dyadic shareholders approve reverse stock split, elect director, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I director Seth J. Herbst, M.D. elected with 18,121,850 votes for, 1,174,107 withheld; 10,313,240 broker non-votes.","Reverse stock split authorized: 25,419,068 for, 3,725,962 against, 464,167 abstained; board may implement at discretion.","Crowe LLP ratified as independent auditor for FY 2026: 28,623,686 for, 517,907 against, 467,604 abstained.","Advisory vote on named executive officer compensation passed: 18,213,001 for, 343,799 against, 739,157 abstained; 10,313,240 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1123476,"accession_number":"0001493152-26-029214","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-06-18T13:55:31+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq delisting notice for bid price and continued listing deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Dyadic on June 18, 2026 of failure to maintain minimum $1.00 bid price and meet continued listing standards.","Company had until June 17, 2026 to cure bid price deficiency; did not comply and also lacked $5M equity for extension.","Continued listing standards require $2.5M equity, $35M market value, or $500K net income; Dyadic fails all.","Dyadic plans to request a hearing before Nasdaq panel, which stays delisting pending decision.","No assurance of regaining compliance; delisting could adversely affect liquidity and capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057437,"accession_number":"0001493152-26-028700","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-06-15T20:30:17+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic highlights accelerated C1 platform interest amid Ebola preparedness and commercial adoption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["C1 platform can produce purified antigen or monoclonal antibody in ~15 days, says company.","Collaborations: Scripps Research (Ebola, hantaviruses); CEPI Ebola funding proposals; Fondazione Biotecnopolo di Siena (Ebola, hantavirus antibodies).","Commercial milestones: recombinant human albumin via Proliant Health; recombinant DNase I via Fermbox Bio; bovine chymosin via Inzymes.","Estimated addressable market >$25B across life sciences, food/nutrition, bioindustrial applications.","DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":706161,"accession_number":"0001493152-26-025554","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-05-28T13:11:20+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic and Scripps Research collaborate on hantavirus antibody and vaccine development using C1 platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus causing Hantavirus Pulmonary Syndrome.","Builds on prior Andes virus monoclonal antibody work; C1 platform aims for rapid, scalable biologic production.","C1 platform previously applied to RSV, malaria, Andes, Ebola, Marburg; demonstrated comparable neutralization to mammalian systems.","Dyadic currently in funded collaborations with Gates Foundation, CEPI, and FBS for accelerating vaccine/antibody development.","Parties plan to explore external partnership and non-dilutive funding opportunities to support further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68287,"accession_number":"0001493152-26-022727","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-05-13T20:11:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.","Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.","Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.","Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.","Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs."],"consensus_eps_estimate":-0.0408,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1110956.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102020,"accession_number":"0001493152-26-013405","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq deficiency notice for continued listing rule non-compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received notice on March 27, 2026 for non-compliance with Nasdaq Listing Rule 5550(b) requiring $2.5M equity, $35M market value, or $500K net income.","Company has 45 days to submit a compliance plan; cure period up to 180 days if plan accepted.","Also remains non-compliant with minimum bid price rule (need $1.00) until June 17, 2026.","Failure to cure either deficiency could lead to delisting of common stock from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102019,"accession_number":"0001493152-26-012673","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic reports FY 2025 net loss of $7.36M; revenue down to $3.09M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities of $8.59M as of Dec 31, 2025, down from $9.29M a year earlier.","Revenue fell to $3.09M from $3.50M; net loss widened to $7.36M ($0.23/sh) from $5.81M ($0.20/sh).","Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant; Dyadic eligible for profit share.","Expanded Fermbox Bio collaboration; commercial launch of recombinant DNase I (RNase-free).","OEM distribution agreement with IBT Bioservices for DNase I and transferrin; BRIG Bio deal for alpha-lactalbumin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102018,"accession_number":"0001493152-26-009179","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic International enters into ATM equity distribution agreement for up to $4.24M with Craig-Hallum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows Dyadic to sell up to $4,237,818 of common stock at prevailing market prices through Craig-Hallum as sales agent.","Craig-Hallum will receive up to 3.0% commission on gross sales price; Dyadic also reimburses certain expenses and provides indemnification.","No obligation to sell any shares; Company may suspend or terminate the offering at any time.","Shares are offered under effective S-3 shelf registration statement (Aug 2023) and prospectus supplement dated March 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118363,"accession_number":"0001493152-25-029351","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic extends convertible note maturity to Dec 2027, conversion price set at $1.05","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of Senior Secured Convertible Notes extended from March 8, 2027 to December 31, 2027.","Conversion price amended to $1.05 per share of common stock.","Holders lose optional redemption right except in event of default under the notes.","Amendment dated December 23, 2025; affects existing notes due March 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118362,"accession_number":"0001493152-25-029141","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq minimum bid price deficiency notice; 180-day cure period through June 17, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Dec 19, 2025; bid price below $1 for 30 consecutive business days.","Company has 180 calendar days, until June 17, 2026, to regain compliance by closing at $1+ for 10 consecutive days.","If not compliant by deadline, may qualify for additional 180-day period subject to meeting other listing criteria.","No immediate impact on Nasdaq Capital Market listing; company evaluating options to cure bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118361,"accession_number":"0001493152-25-021914","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic International Reports Q3 2025 Financial Results and Strategic Progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.","Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.","Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.","Secured ERS Genomics CRISPR license to optimize protein production.","Received $1.5 million in milestone payments from Proliant for animal-free serum albumin."],"consensus_eps_estimate":-0.0442,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2524819.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118360,"accession_number":"0001493152-25-017306","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyadic regains Nasdaq compliance, achieves $750K in milestones with Proliant & Inzymes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq market value ($35M) and bid price ($1.00) rules after 10 consecutive days ending Sept 30 & Oct 2, 2025.","Received $500K milestone from Proliant for recombinant human albumin productivity; payment expected Q4 2025; commercial launch targeted late 2025/early 2026.","Received $250K milestone payment from Inzymes for dairy enzyme productivity improvements; first enzyme scale-up on track for late 2025 launch.","Signed term sheet for development of non-animal human alpha-lactalbumin for infant nutrition; sampling of bovine version underway.","Advancing commercialization of recombinant transferrin and DNase I with ongoing sampling and validation in research/diagnostic markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134802,"accession_number":"0001493152-25-013635","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic amends security agreement; CEO's trust added as secured party for $1M note purchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO Mark Emalfarb purchased and was assigned a $1,000,000 Senior Secured Convertible Promissory Note due March 8, 2027.","Amendment added Mark A. Emalfarb Trust as a secured party with $1,000,000 principal.","Other secured parties updated: Francisco Trust $1M, Barry M. Kitt $1M, CK Management $1M, and others.","Amendment executed September 15, 2025, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134801,"accession_number":"0001641172-25-023496","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).","Cash $7.3M at June 30; $5.3M net from August 1 equity offering (6.052M shares at $0.95).","Rebranded as Dyadic Applied BioSolutions; targeting 2025 commercial launch of animal-free serum albumin with Proliant.","Received $1.5M second installment from Gates Foundation mAb grant; expects $500K Proliant milestone in Q3 2025.","Inzymes milestone $250K received; EN3ZYME enzyme cocktail launched with Fermbox Bio under revenue share."],"consensus_eps_estimate":-0.0612,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1360202.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134800,"accession_number":"0001641172-25-021911","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyadic International prices 6.05M-share public offering at $0.95, net ~$5.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,052,000 shares at $0.95 per share; expected net proceeds approximately $5.3 million.","Craig-Hallum Capital Group LLC acting as sole managing underwriter.","Net proceeds to be used for working capital, product development, sales and marketing.","Offering closed on August 1, 2025; shelf registration effective August 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134799,"accession_number":"0001641172-25-020731","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic posts strategic presentation; no specific financial or operational updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted July 23, 2025 highlights transition from research to commercial focus.","Focus on C1 and Dapibus gene expression platforms for non-therapeutic protein production.","No specific financial targets, revenue guidance, or operational metrics disclosed.","Presentation will be used at industry and investor conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134798,"accession_number":"0001641172-25-020728","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Dyadic that its common stock bid price closed below $1 for 30 consecutive business days, violating Listing Rule 5550(a)(2).","Company has until January 13, 2026 to regain compliance by having bid price close at $1 or more for 10 consecutive trading days.","Dyadic also remains out of compliance with the $35 million minimum Market Value of Listed Securities (MVLS) requirement, with a separate cure deadline of December 20, 2025.","The Company plans to monitor its bid price and evaluate available options to cure the deficiency.","Failure to cure either deficiency could lead to delisting; the Company may appeal any delisting determination to a Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134797,"accession_number":"0001437749-25-021978","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.","Reports $250,000 milestone payment for second non-animal dairy enzyme program.","Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.","Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.","Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151719,"accession_number":"0001437749-25-021420","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dyadic receives Nasdaq deficiency notice for MVLS below $35M threshold","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff notified Dyadic on June 23 that MVLS was below $35M for 30 consecutive business days.","Company has until December 20, 2025 to regain compliance by closing at $35M+ for 10 consecutive days.","If compliance not achieved, common stock may be delisted; company plans to evaluate options.","Notice has no immediate effect on DYAI listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151718,"accession_number":"0001437749-25-021169","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyadic shareholders re-elect Emalfarb, ratify Crowe, and adopt annual say-on-pay at 2025 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mark A. Emalfarb re-elected Class III director with 15,946,385 votes for, 421,896 withheld; 7,892,709 broker non-votes.","Ratification of Crowe LLP as independent auditor passed with 24,013,307 for, 237,523 against, 10,160 abstain.","Advisory say-on-pay vote approved: 15,765,072 for, 522,744 against, 80,465 abstain; 7,892,709 broker non-votes.","Say-on-pay frequency: 15,443,558 votes for 1-year; Board sets future advisory votes every one year.","All four proposals passed at the June 20, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151717,"accession_number":"0001437749-25-019177","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Dyadic appoints Joe Hazelton as President; strategic shift to ancillary proteins with commercial partnerships","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hazelton promoted to President, continues as COO; base salary raised 10% to $320,000; 25,000-share option grant with 4-year vesting.","Strategic pivot to ancillary recombinant proteins for life sciences, nutrition, and industrial markets; validated by partnerships with Proliant Health, dairy enzyme firm, and EN3ZYME.","Legacy biopharma programs remain active under CEO Emalfarb; company to pursue corporate rebranding.","CEO states milestones validate strategy; Hazelton to scale commercialization and drive operational execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151716,"accession_number":"0001437749-25-016867","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.","Net loss $2.028M vs $2.01M YoY; operating loss improved to $2.002M from $2.126M.","Cash, cash equivalents and securities $7.3M at March 31, 2025, down from $9.3M at Dec 31, 2024.","Up to $4.5M CEPI grant and $3M Gates Foundation grant advancing C1 platform for vaccines and antibodies.","Commercial launch of recombinant Human Serum Albumin expected Q3 2025; dairy enzyme launch late 2025."],"consensus_eps_estimate":-0.0408,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":393572.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151715,"accession_number":"0001437749-25-014571","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic amends convertible notes; redemption date moved to Dec 1, 2026","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Second Amendment to Senior Secured Convertible Promissory Notes due March 8, 2027 entered with majority holders.","Redemption date changed to December 1, 2026, earlier than original maturity.","Amendment executed on May 1, 2025; full terms in Exhibit 4.1.","No other financial or operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151714,"accession_number":"0001437749-25-013546","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Arindam Bose to retire at Dyadic's annual meeting on June 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arindam Bose notified Dyadic board of retirement as director.","Retirement effective at June 20, 2025 annual meeting; Bose will serve until then.","Retirement not due to any disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170572,"accession_number":"0001437749-25-009351","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic FY2024: revenue $3.5M (+21%), net loss $5.8M ($0.20/shr), cash $9.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.495M, up from $2.899M in 2023; driven by $1M Proliant license and $890k Inzymes success fees.","Net loss $5.809M ($0.20 per share), improved from $6.795M ($0.24 per share) in 2023.","Cash and investment-grade securities $9.288M at Dec 31, 2024 vs $7.273M at year-end 2023.","Up to $7.5M in grants from CEPI (up to $2.4M for Dyadic) and Gates Foundation for C1 platform.","Human Serum Albumin commercial launch expected Q2 2025; DNase1 advancing with EU CDMO partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170571,"accession_number":"0001437749-25-008493","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dyadic receives $4.5M CEPI grant for C1 fungus-based vaccine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEPI awards $4.5M to non-profit FBS for proof-of-concept using Dyadic's C1 fungus to produce vaccine antigens.","Goal: reduce vaccine production and release time to 35 days, versus 4-6 months for mammalian cell lines.","Project will compare SARS-CoV-2 spike protein produced in C1 vs. mammalian cells for structure and immunogenicity.","Technology aims to enable faster, scalable, and affordable vaccine manufacturing for pandemic response (100 Days Mission).","Dyadic's CEO notes support for global health security and One Health approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187566,"accession_number":"0001437749-24-036247","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.","Targets RSV (100K+ deaths annually, 99% in LMICs) and malaria (249M cases, 608K deaths in 2022).","Aims to reduce production costs and improve global access to affordable therapeutics for underserved populations.","Dyadic plans to commercialize resulting antibodies via licensure if development succeeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187565,"accession_number":"0001437749-24-034551","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.","Net loss of $203K vs $1.614M a year ago; operating loss fell to $203K from $1.720M.","Cash & investment-grade securities at $10.0M as of Sep 30, 2024, up from $7.3M at Dec 31, 2023.","Received $1M milestone from Proliant for animal-free recombinant albumin; first product launch expected H1 2025.","Advanced C1-produced Mpox antigen with ViroVax (4.5 g/L in 7 days); preclinical studies start Q4 2024."],"consensus_eps_estimate":-0.0442,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":2678013.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187564,"accession_number":"0001437749-24-034347","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dyadic formalizes CFO employment agreement; base salary $269,024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Ping Rawson receives annual base salary of $269,024 under new employment agreement.","Eligible for annual target bonus up to 25% of base salary, tied 50% to company performance and 50% to individual goals.","Severance: if terminated without cause or for good reason, receives 12 months base salary and benefits plus pro-rata bonus.","One-year non-compete and two-year non-solicitation of employees, vendors, and customers.","Annual equity awards anticipated as stock options with 4-year vesting; discretionary additional bonuses possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187563,"accession_number":"0001437749-24-030893","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dyadic International amends convertible note terms; conversion price set at $1.40","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Conversion price reduced to $1.40 per share under amendment to Senior Secured Convertible Promissory Note due March 8, 2027.","Redemption date now any of the 26th, 29th, or 32-month anniversaries of the original note issue date.","Amendment executed October 4, 2024; disclosed via Form 8-K on October 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204044,"accession_number":"0001437749-24-026398","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.","Cash and securities $10.1M at June 30, 2024, up from $7.3M at Dec 31, 2023.","Partnered with Proliant Health for animal-free recombinant albumin; $500k initial payment received.","Joint development with a Top 10 global dairy for food-grade alpha-lactalbumin.","Avian flu H5 nanoparticle antigen shows high neutralizing antibody titers in animal studies."],"consensus_eps_estimate":-0.0612,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":720513.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204043,"accession_number":"0001437749-24-021877","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Dyadic enters recombinant albumin partnership with Proliant; $1.5M upfront milestone payments + profit share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.","First product (recombinant human serum albumin) expected to launch in first half of 2025.","Partnership targets ~$6B serum albumin market for cell culture, vaccine, medical device, diagnostic segments.","Dyadic's COO states agreement demonstrates strategy to commercialize products and generate near-term revenue in Alternative Proteins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204042,"accession_number":"0001437749-24-021876","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Dyadic licenses fungal platforms to Proliant for recombinant albumin; up to $1.5M milestones + profit share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.","Dyadic to receive up to $1.5M in milestone payments plus a share of profits from product sales.","First product launch expected in the first half of 2025, targeting the ~$6B serum albumin market.","Proliant will use Dyadic's fungal microbial expression platforms for production."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220751,"accession_number":"0001437749-24-019968","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyadic International reports 2024 annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors Jack L. Kaye (14,971,570 for) and Patrick Lucy (15,039,453 for); 7,115,287 broker non-votes each.","Ratified Crowe LLP as independent auditor with 23,400,950 for (99.78% of votes cast), 49,863 against, 125,721 abstain.","Advisory vote on named executive officer compensation passed with 15,543,521 for (97.76% of votes cast), 354,798 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220750,"accession_number":"0001437749-24-016675","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q1 2024 net loss $2.01M ($0.07/share), revenue $335K; cash $12.1M; Phase 1 COVID booster successful","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.01M ($0.07 per share) vs $0.956M ($0.03) in Q1 2023; revenue down to $335K from $934K.","Cash and securities $12.1M as of Mar 31, 2024, up from $7.3M at Dec 31, 2023.","Phase 1 trial of DYAI-100 COVID booster completed; met safety and antibody response endpoints.","Issued $6.0M convertible notes (8%, due 2027) on Mar 8, 2024; appointed Patrick Lucy Chairman and Joe Hazelton COO.","Multiple collaborations with top pharma, ViroVax for H5N1 vaccine, and other partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":334617.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240367,"accession_number":"0001437749-24-009820","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Dyadic reports FY2023 net loss of $6.8M; appoints new Chairman and COO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.8M ($0.24/share) vs $9.7M loss in 2022; revenue $2.9M flat YoY.","Cash & investments $7.3M at Dec 31, 2023; raised $6M convertible note in March 2024.","Positive Phase 1 topline data for DYAI-100 COVID booster: safe and immunogenic.","Patrick Lucy appointed Chairman, replacing Michael Tarnok (retiring June 2025); Joseph Hazelton named COO.","Entered multiple funded collaborations including top-ten pharma, Phibro/Abic, Rabian, Massachusetts General Hospital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240366,"accession_number":"0001437749-24-007270","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Dyadic closes $6M convertible note financing with insider participation to fund commercialization","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$6M aggregate principal, 8% senior secured convertible notes, due March 2027, conversion at $1.79/share.","Purchasers include CEO Mark Emalfarb's family members and The Francisco Trust (>5% holder).","Net proceeds of ~$5.85M after expenses; intended for working capital and corporate purposes.","Funds to accelerate C1 and Dapibus platform commercialization after positive Phase I clinical results.","Registration rights agreement filed for shares underlying the convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257875,"accession_number":"0001437749-23-030944","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).","Cash $8.2M as of Sep 30, down from $12.7M at Dec 31, 2022.","Received $0.6M upfront in Oct for Dapibus animal-free dairy enzyme license.","DYAI-100 Phase 1 top-line results expected Dec 2023; no major safety concerns.","New collaboration with Mass General/DoD ($5.88M grant) and bYoRNA for mRNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2212271.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257874,"accession_number":"0001437749-23-027858","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dyadic partners with MGH VIC and Voltron for vaccine antigens; part of $5.88M DoD award","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dyadic’s C1 platform to express vaccine antigens for influenza A and other infectious diseases.","Collaboration stems from a $5.88M DoD award to VIC for Self-Assembling Vaccine platform.","Aims to enable scalable, rapid vaccine production in 100 days or less at flexible scales.","Potential commercial revenue for Dyadic if products are brought to market.","Partners include Vaccine and Immunotherapy Center at MGH and Voltron Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257873,"accession_number":"0001437749-23-027854","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Dyadic's collaboration with Janssen terminated; wind-down by Dec 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janssen Biotech provided written notice on Oct 2, 2023 to terminate the Research, License, and Collaboration Agreement with Dyadic.","Collaboration effective end date is December 31, 2023.","Agreement originally entered Dec 16, 2021 for manufacture of therapeutic proteins using Dyadic's C1 platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275214,"accession_number":"0001437749-23-026258","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyadic signs exclusive license deal with INZYMES for dairy enzymes; $0.6M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dyadic receives $0.6M upfront for development and licensing of Dapibus platform to INZYMES.","Exclusive license targets non-animal dairy enzymes used in food production.","Potential success fees, milestones, and royalties beyond upfront payment.","Addressable alternative protein market cited at >$60B, growing to $190B by 2028.","Deal builds on previous success producing animal-free casein proteins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275213,"accession_number":"0001437749-23-022782","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q2 net loss narrows to $2.15M; positive Phase 1 safety data for COVID booster DYAI-100","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.15M (-$0.07/sh) vs -$3.29M (-$0.12/sh) YoY; revenue $837K up from $659K.","Positive interim Phase 1 data: no major safety issues, immune response at both low and high doses of DYAI-100.","Cash $10.2M at June 30, 2023, down from $12.7M at Dec 31, 2022.","New fully funded collaborations: Top 5 pharma for vaccine antigen, EDCL in Bangladesh, Fermbox for alternative proteins.","Developed animal-free recombinant serum albumin; structurally equivalent to animal-derived product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1815211.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292650,"accession_number":"0001437749-23-017505","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K/A","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyadic International files amended 8-K correcting 2023 annual meeting vote results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: Seth J. Herbst elected with 15,207,883 for, 780,295 withheld; Arindam Bose with 15,832,192 for, 155,986 withheld.","Proposal 2: Ratification of Crowe LLP as auditor approved with 23,358,598 for (99.88% of votes cast), 26,157 against, 6,905 abstained.","Proposal 3: Advisory vote on executive compensation approved with 15,549,508 for (97.61% of votes cast), 380,176 against, 58,494 abstained.","Broker non-votes: 7,403,482 on Proposals 1 and 3; none on Proposal 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292654,"accession_number":"0001437749-23-017151","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyadic International annual meeting results: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Seth J. Herbst (15,200,953 for, 780,295 withheld) and Arindam Bose (15,825,262 for, 155,986 withheld) elected.","Ratification of Crowe LLP as independent auditor for FY2023 approved with 99.88% of votes cast (23,358,535 for, 26,165 against, 6,961 abstained).","Advisory vote on executive compensation approved with 97.61% of votes cast (15,542,578 for, 380,176 against, 58,494 abstained).","Broker non-votes: 7,410,413 on all proposals except auditor ratification (no broker non-votes on that proposal)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292653,"accession_number":"0001437749-23-013644","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.","Cash and securities $11.8M at Mar 31, 2023, down from $12.7M at Dec 31, 2022.","Received ~$1.27M from sale of minority stake in Alphazyme in Jan 2023.","DYAI-100 booster vaccine dosing completed; no serious adverse events; safety report due June 2023.","Expanded collaborations with Rubic One Health (Africa) and new top-5 pharma research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":978052.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292652,"accession_number":"0001437749-23-010055","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyadic expands C1 platform licensing deal with Rubic One Health for Africa vaccines and biologics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded license covers vaccines and therapeutic proteins beyond COVID-19 for human and animal health.","Rubic to pay licensing fee on commercial sales; Dyadic receives equity in Rubic in 2028.","Milestones allow conversion to exclusive license for bulk manufacturing in SADC region.","DYAI-100 (COVID-19 vaccine candidate) is in Phase 1 first-in-human trial, enabling the expansion.","Agreement aims to develop affordable biologics for underserved African countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292651,"accession_number":"0001437749-23-009856","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Dyadic International appoints Crowe LLP as new independent auditor after prior auditor resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mayer Hoffman McCann resigned as auditor effective upon filing of FY2022 10-K.","Audit committee approved Crowe LLP as successor on April 10, 2023.","Company did not consult Crowe on any accounting principles or disagreements prior to engagement.","No reportable events or disagreements between company and prior auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313303,"accession_number":"0001437749-23-008429","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyadic reports 2022 revenue up 21.9% to $2.93M; net loss narrows to $9.7M; COVID-19 vaccine trial dosing complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.93M (+21.9% YoY); net loss $9.7M ($0.34/share) vs $13.1M ($0.47) in 2021.","Cash $12.7M at year-end; received $1.27M from Alphazyme sale in Jan 2023; expects to fund ops into 2024.","Phase 1 trial of DYAI-100 COVID-19 booster: dosing complete in low/high dose groups, no serious adverse events; full report H2 2023.","Collaborations with Janssen, Phibro/Abic, global food ingredient company; Dapibus platform progress.","Five peer-reviewed publications on C1-cell platform; new corporate website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313302,"accession_number":"0001437749-23-008314","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Dyadic International amends bylaws to align with SEC Rule 14a-19 and Delaware law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended and restated bylaws effective March 28, 2023.","Amendments address Rule 14a-19 universal proxy requirements.","Amendments incorporate recent changes to Delaware General Corporation Law.","No other material changes to governance structure disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313301,"accession_number":"0001437749-23-005594","cik":1213809,"company_name":"DYADIC INTERNATIONAL INC","ticker":"DYAI","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.","No serious adverse events reported; vaccine well tolerated to date.","Initial safety and antibody response update expected in Q2 2023.","First human test of C1-cell platform for vaccines; CEO notes increased interest from academia/industry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25026099.042505596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-07T23:59:59+00:00|313301"}